Latest Current Report
Filed: 2026-04-28
Key Insights
- Arcellx acquisition by Gilead Sciences completed on April 28, 2026 at $115.00 per share in cash plus one CVR worth up to $5.00 per share (payable March 31, 2030), representing a total deal value of $120 per share contingent on anito-cel product sales exceeding $6.0 billion by December 31, 2029.
- Tender offer achieved 77.2% acceptance rate (38.8 million shares) by April 27, 2026, exceeding the 50% threshold required under Delaware law Section 251(h) and enabling short-form merger completion without stockholder vote.
- Contingent Value Right structure ties future shareholder payments to anito-cel commercial success, indicating Gilead's confidence in the product pipeline while reducing upfront acquisition cost and aligning incentives with revenue milestones.
- Transaction completion signals successful exit for Arcellx shareholders with immediate cash payment, though CVR realization depends on achieving substantial $6.0 billion cumulative sales threshold over 3.75 years, representing meaningful execution risk.